Cancer immunotherapies by design, and in development.

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Following is a list of drug combinations currently under study with:

Belrestotug (EOS-448)

as well as the indication for each.

drug combo and indication:

+ dostarlimab | 1L NSCLC PDL1high

status of study phases:

Phase 3, planned

drug combo and indication:

+ dostarlimab | 1L NSCLC PDL1highGALAXIES LUNG-201

status of study phases:

Phase 2, active trial ID GALAXIES-LUNG-201

drug combo and indication:

+ dostarlimab + CD96 | 1L HNSCC PDL1+ | GALAXIES H&N-202

status of study phases:

Phase 2, active trial ID GALAXIES-H&N-202

drug combo and indication:

+ dostarlimab | 1L HNSCC PDL1high / low | TIG-006

status of study phases:

Phase 2, active, trial ID TIG-006

drug combo and indication:

+ dostarlimab + chemotherapy | 1L mNSCLC | TIG-006

status of study phases:

Phase 1, active, trial ID TIG-006

drug combo and indication:

+ dostarlimab + CD96 | Advanced Malignancies | NCT03739710

status of study phases:

Phase 1, active, trial ID NCT03739710

drug combo and indication:

+ dostarlimab + PVRIG | Advanced Malignancies | NCT05277051

status of study phases:

Phase 1, active, trial ID NCT05277051

Following is a list of drug combinations currently under study with:

Inupadenant

as well as the indication for each.

drug combo and indication:

+ chemotherapy | Post-IO Chemo-naive NSCLC | A2A-005

status of study phases:

Phase 2, active, trial ID A2A-005

Following is a list of drug combinations currently under study with:

EOS-984

as well as the indication for each.

drug combo and indication:

Monotherapy | Advanced Malignancies

status of study phases:

Phase 1, planned

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

Child kissing older woman on cheek.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.

We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.